MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Consensus Ratings for Agile Therapeutics (NASDAQ:AGRX) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.50 (102.63% upside)

Analysts' Ratings History for Agile Therapeutics (NASDAQ:AGRX)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2015Cantor FitzgeraldReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015FBR & Co.Initiated CoverageOutperform$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Cantor FitzgeraldReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014Cantor FitzgeraldInitiated CoverageBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014William BlairInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014Janney Montgomery ScottInitiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2014RBC CapitalInitiated CoverageOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/1/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha